|1.||Gitton, Xavier: 11 articles (08/2008 - 08/2004)|
|2.||Krammer, Gerhard: 9 articles (08/2008 - 08/2004)|
|3.||Schnitzer, Thomas J: 5 articles (11/2011 - 08/2004)|
|4.||Krammer, G: 5 articles (05/2010 - 11/2004)|
|5.||Matchaba, Patrice: 5 articles (08/2008 - 08/2004)|
|6.||Mellein, Bernhard: 5 articles (08/2008 - 08/2004)|
|7.||Hawkey, Christopher J: 5 articles (05/2008 - 08/2004)|
|8.||Prous, J R: 5 articles (09/2007 - 01/2003)|
|9.||Rabasseda, X: 5 articles (09/2007 - 01/2003)|
|10.||Sloan, Victor S: 5 articles (02/2006 - 08/2004)|
10/01/2005 - "Single 200 or 400 mg doses of lumiracoxib provided rapid and effective relief from the acute pain associated with ETTH."
11/01/2004 - "Lumiracoxib demonstrated significant improvement in OA pain intensity, patients global assessment of disease activity, and the WOMAC pain subscale and total scores compared with placebo. "
09/01/2004 - "Lumiracoxib significantly improved overall OA pain intensity in the target hand versus placebo, with a tolerability profile similar to placebo."
08/15/2004 - "Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. "
11/01/2011 - "In conclusion, lumiracoxib is effective in reducing pain and improving function in hip OA patients."
01/01/2005 - "Efficacy of lumiracoxib in osteoarthritis: a review of nine studies."
02/01/2013 - "Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis."
01/01/2005 - "In addition, lumiracoxib was consistently superior to placebo and generally similar to active comparators in terms of the new Outcome Measures in Clinical Trials and Osteoarthritis Research Society International criteria. "
06/01/2012 - "As with the other six cases reported to the TGA, all were females who had been taking lumiracoxib 200-400 mg daily, typically for a few months, for osteoarthritis. "
07/01/2008 - "Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee."
04/01/2005 - "Furthermore, lumiracoxib 200 - 400 mg/day appeared to be effective in patients with rheumatoid arthritis. "
01/01/2005 - "In patients with rheumatoid arthritis, peak lumiracoxib synovial fluid concentrations occur 3-4 hours later than in plasma and exceed plasma concentrations from 5 hours after dosing to the end of the 24-hour dosing interval. "
11/01/2004 - "A randomised, double-blind study was performed to assess the efficacy and tolerability of lumiracoxib in patients with rheumatoid arthritis (RA). "
11/01/2004 - "Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis."
01/01/2004 - "These data support the use of lumiracoxib in a once-daily regimen for the treatment of rheumatoid arthritis."
05/01/2008 - "The large (n = 18 325) Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) study demonstrated a significant gastrointestinal benefit with lumiracoxib 400 mg o.d. "
05/01/2008 - "Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial."
07/01/2007 - "Data from the Therapeutic Arthritis Research and Gastrointestinal Event Trial were used to identify risk factors and investigate the safety of lumiracoxib in subgroups. "
07/01/2004 - "Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics."
02/01/2005 - "The safety of lumiracoxib when used in the treatment of arthritis."
|5.||Tension-Type Headache (Tension Headache)
10/01/2005 - "Lumiracoxib is effective in the treatment of episodic tension-type headache."
10/01/2005 - "To evaluate the efficacy of single doses of lumiracoxib, the most selective cyclo-oxygenase (COX)-2 inhibitor, in the treatment of episodic tension-type headache (ETTH), with particular emphasis on time to onset of analgesia. "
01/01/2004 - "In single- and multiple-dose well designed trials in patients with acute pain associated with primary dysmenorrhoea, dental or orthopaedic surgery or tension-type headache, lumiracoxib 100-800 mg once daily was more effective in relieving acute pain than placebo or controlled-release oxycodone 20 mg, and was at least as effective as selective COX-2 inhibitors or nonselective NSAIDs. "
|3.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|6.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|7.||Aspirin (Acetylsalicylic Acid)
|10.||Cyclooxygenase 2 (Cyclooxygenase-2)
|4.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)